In the specific context of pancreatic cancer, a reassessment of small molecule inhibitors of downstream effectors of KRAS in the context of our chemically engineered vulnerability is therefore warranted based upon forcing interactome hyperconnectivity states. This evidence concerns the gene KRAS and pancreatic neoplasm.